Alvimopan (Adolor/GlaxoSmithKline).
| Title: | Alvimopan (Adolor/GlaxoSmithKline). |
|---|---|
| Authors: | Azodo IA; University of Chicago, Department of Medicine, IL 60637, USA.; Ehrenpreis ED |
| Source: | Current opinion in investigational drugs (London, England : 2000) [Curr Opin Investig Drugs] 2002 Oct; Vol. 3 (10), pp. 1496-501. |
| Publication Type: | Journal Article; Review |
| Language: | English |
| Journal Info: | Publisher: Thomson Reuters (Scientific) Ltd Country of Publication: England NLM ID: 100965718 Publication Model: Print Cited Medium: Print ISSN: 1472-4472 (Print) Linking ISSN: 14724472 NLM ISO Abbreviation: Curr Opin Investig Drugs Subsets: MEDLINE |
| Imprint Name(s): | Publication: London : Thomson Reuters (Scientific) Ltd; Original Publication: London, UK : Published by PharmaPress Ltd in association with Current Drugs Ltd, c2000- |
| MeSH Terms: | Narcotic Antagonists/*therapeutic use ; Piperidines/*therapeutic use ; Receptors, Opioid, mu/*antagonists & inhibitors; Piperidines/metabolism ; Piperidines/pharmacology ; Animals ; Clinical Trials as Topic ; Humans ; Structure-Activity Relationship |
| Abstract: | Alvimopan is a potent, peripherally active, mu-opioid receptor antagonist being developed by Adolor and GlaxoSmithKline (GSK) as a potential treatment for post-operative ileus and opioid bowel dysfunction. |
| Number of References: | 35 |
| Comments: | Erratum in: Curr Opin Investig Drugs. 2003 Jan;4(1):96. |
| Substance Nomenclature: | 0 (Narcotic Antagonists); 0 (Piperidines); 0 (Receptors, Opioid, mu); 677C126AET (alvimopan) |
| Entry Date(s): | Date Created: 20021115 Date Completed: 20030411 Latest Revision: 20130527 |
| Update Code: | 20260130 |
| PMID: | 12431026 |
| Database: | MEDLINE |
Journal Article; Review